Protocol Ledger

NCT05119907 · Phase II · ACTIVE NOT RECRUITING

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Interventional Phase II clinical trial protocol NCT05119907 sponsored by Gilead Sciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-12 Enrollment: 53 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05119907
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)53 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05119907
Protocol FieldVerified Registry Value
NCT IdentifierNCT05119907
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment53 participants (ACTUAL)
Registered Start Date2021-10-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI